Brief: Dogwood Therapeutics Announces Pricing Of $4.8 Million Registered Direct Offering Of Common Stock Priced At-The-Market Under Nasdaq Rules
13/03/2025 14:46
March 13 (Reuters) - Dogwood Therapeutics Inc DWTX.O: DOGWOOD THERAPEUTICS, INC. ANNOUNCES PRICING OF $4.8 MILLION REGISTERED DIRECT OFFERING OF COMMON STOCK PRICED AT-THE-MARKET UNDER NASDAQ RULES DOGWOOD THERAPEUTICS INC: PROCEEDS FROM FINANCING, WHEN ADDED TO EXISTING CASH, FUND OPERATIONS THROUGH Q1 2026 Source text: ID:nGNX3kfxgV Further company coverage: DWTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Dogwood Therapeutics
See all newsDogwood Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Dogwood Therapeutics Q2 net loss widens on higher costs, impairment charge
Brief: Dogwood Therapeutics Q2 EPS USD -0.34
Dogwood Therapeutics Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Dogwood Therapeutics Announces Commencement Of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2B Long Term Extension Study